Literature DB >> 6849782

Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration.

N P Vermeulen, C T Rietveld, D D Breimer.   

Abstract

1 Hexobarbitone plasma kinetics were determined in six healthy volunteers, who received 500 mg hexobarbitone orally. In addition urinary excretion rate and cumulative excretion were measured of its three major metabolites: 3'-hydroxyhexobarbitone, 3'-ketohexobarbitone and 1,5-dimethylbarbituric acid. 2 The mean plasma elimination half-life of hexobarbitone was 3.7 +/- 0.9 h (n = 6). Assuming complete absorption, the volume of distribution and the metabolic clearance were 81.3 +/- 20.5 1 and 16.4 +/- 2.9 1/h, respectively. The mean maximal plasma concentration was 7.1 +/- 2.1 micrograms/ml and was reached 1.2 +/- 0.4 h after drug administration. 3 3'-Hydroxyhexobarbitone and 3'-ketohexobarbitone, which are products of allylic side-chain oxidation of hexobarbitone, were excreted in 24 h to the extent of 4.7 +/- 1.3 and 32.1 +/- 11.9% of the dose, respectively. In the same period, 1,5-dimethylbarbituric acid, which is the end product of the epoxide-diol pathway, was excreted to 18.0 +/- 7.8% of the dose. The ratio of the sum of 3'-hydroxy- and 3'-ketohexobarbitone vs 1,5-dimethylbarbituric acid excreted varied with time and amounted ultimately in 24 h urine to 2.3 +/- 1.0. 4 The half-lives of 3'-hydroxyhexobarbitone and 1,5-dimethylbarbituric acid, calculated from their renal excretion rate curves, amounted 5.2 +/- 0.9 and 6.6 +/- 1.3 h and were significantly longer than the half-life of hexobarbitone in plasma. The half-life of 3'-ketohexobarbitone was 4.2 +/- 0.8 h. The maximum excretion rate of 1,5-dimethylbarbituric acid was reached at 7.7 +/- 1.0 h after administration of hexobarbitone. 3'-Hydroxy- and 3'-ketohexobarbitone were excreted with a maximal rate at 2.2 +/- 0.8 and 2.8 +/- 0.4 h respectively.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849782      PMCID: PMC1427803          DOI: 10.1111/j.1365-2125.1983.tb01530.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery.

Authors:  D D Breimer; W Zilly; E Richter
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].

Authors:  E Richter; H Gallenkamp; B Keller; D Brachtel; W Zilly; D D Breimer
Journal:  Z Gastroenterol       Date:  1977-06       Impact factor: 2.000

3.  Rapid and sensitive gas chromatographic determination of hexobarbital in plasma of man using a nitrogen detector.

Authors:  D D Breimer; J M Van Rossum
Journal:  J Chromatogr       Date:  1974-01-30

4.  The metabolic fate of hexobarbital in the rat.

Authors:  R R Holcomb; N Gerber; M T Bush
Journal:  J Pharmacol Exp Ther       Date:  1974-01       Impact factor: 4.030

5.  Hexobarbital disposition in compensated and decompensated cirrhosis of the liver.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

6.  The epoxide-diol pathway in the metabolism of hexobarbital in rat and man.

Authors:  N P Vermeulen; B H Bakker; J Schultink; A van der Gen; D D Breimer
Journal:  Xenobiotica       Date:  1979-05       Impact factor: 1.908

7.  Hexobarbital-1',2'-epoxide: a possible intermediate in the metabolism of hexobarbital.

Authors:  N P Vermeulen; P J van Bladeren; D D Breimer; A van der Gen
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

8.  Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.

Authors:  M Danhof; D P Krom; D D Breimer
Journal:  Xenobiotica       Date:  1979-11       Impact factor: 1.908

9.  Pharmocokinetics of hexobarbital in man after intravenous infusion.

Authors:  D D Breimer; C Honhoff; W Zilly; E Richter; J M van Rossum
Journal:  J Pharmacokinet Biopharm       Date:  1975-02

10.  Amobarbital metabolism in man: N-glucoside formation.

Authors:  B K Tang; W Kalow; A A Grey
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-07
View more
  1 in total

1.  Disposition of allylic oxidation pathway metabolites of racemic hexobarbital in the rat.

Authors:  M Van der Graaff; N P Vermeulen; M H Vinks; D D Breimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.